Revvity (NYSE:RVTY) Hits New 12-Month High – What’s Next?

Revvity Inc. (NYSE:RVTY) shares hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $134.37 and last traded at $135.1170, with a volume of 117173 shares trading hands. The stock had previously closed at $128.49.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. UBS Group initiated coverage on Revvity in a research report on Wednesday, September 9th. They set a “neutral” rating and a $140.00 price target on the stock. KeyCorp boosted their price objective on Revvity from $125.00 to $165.00 and gave the company an “overweight” rating in a research note on Friday, September 4th. Wolfe Research initiated coverage on shares of Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating on the stock. Zacks Research upgraded shares of Revvity from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 4th. Finally, Weiss Ratings upgraded shares of Revvity from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, July 30th. Four equities research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $116.57.

Revvity Price Performance

The business’s 50-day moving average price is $119.31 and its 200 day moving average price is $104.10. The company has a market capitalization of $16.30 billion, a P/E ratio of 69.54, a price-to-earnings-growth ratio of 2.55 and a beta of 1.09. The company has a quick ratio of 1.50, a current ratio of 1.80 and a debt-to-equity ratio of 0.36.

Revvity (NYSE:RVTY) last posted its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share for the quarter, topping analysts’ consensus estimates of $1.21 by $0.20. Revvity had a net margin of 8.16% and a return on equity of 8.34%. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. During the same quarter in the prior year, the firm posted $1.18 EPS. Revvity’s revenue was down 1.3% on a year-over-year basis. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. Analysts anticipate that Revvity Inc. will post 5.36 EPS for the current fiscal year.

Revvity Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 13th. Stockholders of record on Friday, October 23rd will be issued a $0.07 dividend. The ex-dividend date of this dividend is Friday, October 23rd. This represents a $0.28 annualized dividend and a dividend yield of 0.2%. Revvity’s dividend payout ratio is presently 13.33%.

Institutional Investors Weigh In On Revvity

Several large investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its position in Revvity by 5.8% during the second quarter. The Manufacturers Life Insurance Company now owns 368,938 shares of the company’s stock worth $41,048,000 after buying an additional 20,278 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new stake in shares of Revvity in the 2nd quarter valued at about $171,000. Nykredit A S purchased a new stake in shares of Revvity in the 2nd quarter valued at about $358,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of Revvity in the 2nd quarter valued at about $823,000. Finally, Angeles Wealth Management LLC boosted its position in shares of Revvity by 2.0% during the 2nd quarter. Angeles Wealth Management LLC now owns 5,804 shares of the company’s stock valued at $646,000 after acquiring an additional 112 shares during the last quarter. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a life sciences and diagnostics company that provides technologies, products and services used by researchers, healthcare professionals and laboratories. Its offerings support applications across genomics, proteomics, cellular analysis, drug discovery, disease research and laboratory testing.

The company develops and supplies scientific instruments, reagents, consumables, software and workflow solutions. Its portfolio includes platforms for genetic and molecular analysis, imaging, high-throughput screening, biomarker research and single-cell analysis, as well as laboratory solutions used in areas such as reproductive health and newborn screening.

Revvity was established in 2023 following the separation of PerkinElmer’s Applied, Food and Enterprise Services businesses from its Precision Diagnostics operations.